Cooperative Agreement U01CK000666

This Project Grant from the National Science Foundation's Social, Behavioral, and Economic Sciences program provides $198,092 to fund a survey-based research project examining risk perceptions and behavioral intentions related to the 2022 monkeypox outbreak. The award was made to The Research Foundation for the State University of New York on November 1, 2022, with a completion date of October 31, 2023. Specifically, the funding will support a large-scale survey of 1,000 individuals to...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $547,988 Project Grant to the University of Pittsburgh under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 11, 2025. The funding supports the development and testing of a novel monkeypox vaccine based on a replication-inducible version of the ACAM2000 smallpox vaccine. The proposed vaccine aims to retain the immunogenicity of ACAM2000 while reducing adverse side effects, particularly for...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $431,750 Project Grant to Arizona State University (ASU) to develop a safer and more effective vaccine for monkeypox/smallpox. The funding, provided through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), will support the establishment of a monkeypox skin cast/EIJ mouse model to evaluate the virulence of multiple monkeypox virus strains and assess the efficacy of a novel, highly...

This $199,775 Project Grant from the National Science Foundation Division of Environmental Biology will support research at the University of California, Los Angeles to develop models to understand and predict the spread of monkeypox virus. The research will analyze monkeypox virus surveillance data and transmission patterns in both core and non-core populations. Mathematical models will be built to design disease control strategies, such as comparing outcomes from reducing transmission in...

This $228,435 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on January 16, 2025. The grant supports research to uncover the mechanisms enabling the cross-species jumps of viruses, such as the SARS-CoV-2 pandemic and monkeypox (mpox) epidemic, focusing on the Myxoma virus (MYXV) as a model system. The research aims to study the evolution and host adaptation of MYXV,...

This $2,777,976 Cooperative Agreement, awarded by the U.S. Agency for International Development (USAID) under the USAID Foreign Assistance for Programs Overseas (CFDA 98.001) program, aims to improve the response to HIV and ensure sustained epidemic control in targeted areas of the Democratic Republic of Congo (DRC). The primary awardee, Family Health International (FHI 360), will implement activities to decrease new HIV infections and reduce HIV-associated morbidity and mortality in the...

This $221,105 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is supporting research to investigate how poxviruses, such as monkeypox, can rapidly diversify their genomes to overcome host immune defenses. The research aims to advance understanding of the mechanisms by which host APOBEC enzymes can both restrict and promote viral evolution, with the goal of informing strategies to...

This $260,109 cooperative agreement from the Uniformed Services University of the Health Sciences will support surveillance for Rift Valley fever, rickettsia, malaria, dengue, chikungunya, and Crimean-Congo hemorrhagic fever disease pathogens. The Henry M. Jackson Foundation for the Advancement of Military Medicine will collect human samples and arthropod vectors from selected sites in Botswana to test for these pathogens. Under a subaward, Virginia Polytechnic Institute and State University...

This Project Grant award of $190,261 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund a longitudinal cohort study on Plasmodium vivax (PV) malaria relapses in Central Africa. The study aims to understand the proportion of PV infections that have relapses, the periodicity of relapses, the genetic diversity of relapse parasites compared to primary infections, and the potential for relapse infections to contribute to...

This $100,000 Project Grant awarded on June 3, 2024 by the U.S. Department of State Bureau of African Affairs under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Program (CFDA 19.029) will support community-led monitoring to improve healthcare services in Kinshasa, Democratic Republic of the Congo. The prime awardee, Miscellaneous Foreign Awardees (doing business as Federal Egov IAE Initiative - Generic Entity Identifier), will utilize the funding over the 12-month period ending...